Ganaplacide
- Generic Name
- Ganaplacide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23F2N5O
- CAS Number
- 1261113-96-5
- Unique Ingredient Identifier
- 85VMN9JU7A
- Background
Ganaplacide is under investigation in clinical trial NCT03167242 (Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria).
- Associated Conditions
- -
- Associated Therapies
- -
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05330273
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05236530
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT05084651
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath